|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.18 USD | +0.34% |
|
+7.05% | -7.52% |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,436 | 10,512 | 10,021 | 9,436 | - | - |
| Change | - | 631.97% | -4.67% | -5.84% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 9,228 | 9,338 | 9,153 |
| Change | - | 631.97% | -9.69% | -2.78% | 1.18% | -1.98% |
| P/E ratio | -2.62x | -58.1x | -12.2x | -13.8x | -13.7x | -90.7x |
| PBR | - | - | 20.7x | 63.1x | 140x | 27.1x |
| PEG | - | 0.8x | -0x | 0.8x | -20.03x | 1.1x |
| Capitalization / Revenue | - | - | - | 1,433x | 146x | 14.8x |
| EV / Revenue | - | - | - | 1,401x | 145x | 14.4x |
| EV / EBITDA | - | -96.9x | -11.7x | -18.3x | -18.7x | -48x |
| EV / EBIT | - | -58.8x | -11.7x | -13.4x | -13.3x | -36x |
| EV / FCF | - | -93.4x | -39.6x | -14.3x | -11.8x | -12.9x |
| FCF Yield | - | -1.07% | -2.52% | -7.01% | -8.51% | -7.75% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8801 | -0.8861 | -0.1342 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 6.586 | 64.5 | 636.1 |
| EBITDA 1 | - | -108.4 | -810.4 | -503.3 | -500.2 | -190.8 |
| EBIT 1 | - | -178.8 | -810.5 | -691.1 | -704.6 | -254.1 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -680.7 | -709.3 | -107 |
| Net Debt 1 | - | - | -528.6 | -207.9 | -98.6 | -283.4 |
| Reference price 2 | 2.05 | 14.25 | 13.00 | 12.17 | 12.17 | 12.17 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 775,373 | - | - |
| Announcement Date | 20/02/24 | 24/02/25 | 23/02/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.42x | 6446.99x | -18.43x | -.--% | 12.5B | |
| 41.47x | 9.67x | 34.91x | 0.03% | 42.98B | |
| 15.59x | 5.55x | 12.22x | 1.92% | 39.24B | |
| -51.87x | 17.31x | -57.69x | -.--% | 30.07B | |
| -17.46x | 4.3x | -8.04x | -.--% | 21.88B | |
| 27.73x | 5.41x | 15.05x | -.--% | 18.25B | |
| 21.68x | 4.07x | 13.29x | -.--% | 16.03B | |
| -316.87x | 26.28x | 1446.95x | -.--% | 12.97B | |
| -164.89x | 40.26x | -159.9x | -.--% | 11.76B | |
| 13.48x | 3.75x | 8.89x | -.--% | 10.71B | |
| Average | -44.55x | 656.36x | 128.72x | 0.19% | 21.64B | |
| Weighted average by Cap. | -22.08x | 382.89x | 79.98x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition